← Back to Screener
Incyte Genomics Inc (INCY)
Price$102.38
Value ScoreC
Growth ScoreA
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)-9.92%
Price vs S&P 500 (4W)3.89%
VGM Score69.58
Market Capitalization$20.45B
P/E Ratio (Annual)15.90x
All Metrics
P/CF (Annual)14.47x
Book Value / Share (Quarterly)$28.12
P/TBV (Annual)3.84x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)14.84%
Cash Flow / Share (Quarterly)$7.26
Price vs S&P 500 (YTD)-4.50%
Gross Margin (TTM)92.97%
Net Profit Margin (TTM)26.71%
EPS (TTM)$7.07
10-Day Avg Trading Volume1.75M
EPS Excl Extra (TTM)$7.07
Revenue Growth (5Y)14.03%
EPS (Annual)$6.41
ROI (Annual)24.73%
Gross Margin (Annual)93.26%
Net Profit Margin (5Y Avg)16.76%
Cash / Share (Quarterly)$20.08
P/E Basic Excl Extra (TTM)14.29x
Revenue Growth QoQ (YoY)20.87%
P/E Normalized (Annual)15.90x
ROA (Last FY)18.49%
Revenue Growth TTM (YoY)21.48%
EBITD / Share (TTM)$8.07
ROE (5Y Avg)14.06%
Operating Margin (TTM)30.05%
Cash Flow / Share (Annual)$6.83
P/B Ratio3.64x
P/B Ratio (Quarterly)3.33x
Net Income / Employee (Annual)$452,400
EV / Revenue (TTM)3.18x
Net Interest Coverage (TTM)6.86x
ROA (TTM)21.65%
EPS Growth QoQ (YoY)83.74%
EV / EBITDA (TTM)10.40x
EPS Incl Extra (Annual)$6.41
Current Ratio (Annual)3.32x
Quick Ratio (Quarterly)3.40x
3-Month Avg Trading Volume1.61M
52-Week Price Return52.26%
EV / Free Cash Flow (Annual)12.57x
P/E Incl Extra (TTM)14.29x
Revenue / Employee (TTM)$1,885,000
Tangible BV / Share (Quarterly)$27.57
P/S Ratio (Annual)3.98x
Asset Turnover (Annual)0.74x
52-Week High$112.29
Operating Margin (5Y Avg)16.88%
EPS Excl Extra (Annual)$6.41
CapEx CAGR (5Y)-20.67%
Tangible BV CAGR (5Y)15.67%
26-Week Price Return-1.99%
Quick Ratio (Annual)3.04x
13-Week Price Return5.19%
Total Debt / Equity (Annual)0.01x
Current Ratio (Quarterly)3.68x
Enterprise Value$17.03B
Revenue / Share Growth (5Y)15.94%
Asset Turnover (TTM)0.81x
Book Value / Share Growth (5Y)16.96%
Revenue / Employee (Annual)$1,807,800
Inventory Turnover (Annual)4.33x
Pretax Margin (Annual)32.37%
Cash / Share (Annual)$18.04
3-Month Return Std Dev28.40%
Gross Margin (5Y Avg)94.07%
Net Income / Employee (TTM)$503,400
EBITDA Interim CAGR (5Y)24.21%
ROE (Last FY)24.90%
Net Interest Coverage (Annual)12.38x
EPS Basic Excl Extra (Annual)$6.41
P/FCF (TTM)14.10x
Receivables Turnover (TTM)5.72x
EV / Free Cash Flow (TTM)11.74x
Total Debt / Equity (Quarterly)0.01x
EPS Incl Extra (TTM)$7.07
Receivables Turnover (Annual)5.48x
ROI (TTM)28.99%
P/S Ratio (TTM)3.82x
Pretax Margin (5Y Avg)19.42%
Revenue / Share (Annual)$25.62
Tangible BV / Share (Annual)$25.45
Forward P/E11.77x
Price vs S&P 500 (52W)27.89%
P/E Ratio (TTM)14.29x
EPS Growth TTM (YoY)2455.31%
Year-to-Date Return3.65%
5-Day Price Return7.10%
EPS Normalized (Annual)$6.41
ROA (5Y Avg)10.59%
Net Profit Margin (Annual)25.03%
Month-to-Date Return5.83%
Cash Flow / Share (TTM)$2.23
EBITD / Share (Annual)$7.68
EPS Growth (3Y)61.53%
Operating Margin (Annual)29.46%
LT Debt / Equity (Annual)0.00x
P/CF (TTM)13.48x
ROI (5Y Avg)13.96%
P/E Excl Extra (TTM)14.29x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$7.07
P/TBV (Quarterly)3.40x
P/B Ratio (Annual)3.75x
Inventory Turnover (TTM)4.20x
Pretax Margin (TTM)33.09%
Book Value / Share (Annual)$26.04
Price vs S&P 500 (13W)-3.07%
Beta0.78x
P/FCF (Annual)15.10x
Revenue / Share (TTM)$25.92
ROE (TTM)29.20%
52-Week Low$66.74
vGradeC
gGradeA
mGradeB
vgmGradeB
Show chart for
Earnings Surprise History
Q1 261.81est. 1.40
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
3.76
3.70
3.70
3.66
Industry Peers — R&D — Physical Sciences(15)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
INCYIncyte Genomics Inc | C | A | B | $102.38 |
| IQVIQVIA Holdings Inc. | C | B | C | $183.45 |
| MEDPMedpace Holdings, Inc. Common Stock | D | A | B | $454.25 |
| ICLRIcon Plc | C | C | B | $149.45 |
| CRLCharles River Laboratories International, Inc. | D | D | B | $181.34 |
| ABSIAbsci Corporation Common Stock | F | F | A | $6.40 |
| NRCNRC Health Common Stock | D | D | B | $19.14 |
| OABIOmniAb, Inc. Common Stock | D | C | A | $2.48 |
| MXCTMaxCyte, Inc. Common Stock | C | D | C | $1.14 |
| ONMDOneMedNet Corp Class A Common Stock | D | C | B | $0.68 |
| BIAFbioAffinity Technologies, Inc. Common Stock | C | F | B | $1.73 |
About
Incyte is a biopharmaceutical company specializing in small-molecule therapies for oncology, rheumatology, and dermatology. Jakafi, its flagship product for rare blood cancers and graft versus host disease, is co-developed with Novartis. The company markets multiple approved drugs including Olumiant (with Eli Lilly), Iclusig, Pemazyre, Tabrecta, Monjuvi, and the dermatology product Opzelura for atopic dermatitis and vitiligo. Its pipeline includes additional oncology and dermatology candidates.